Adimab
Kevin Schutz is a highly experienced professional in antibody discovery, with over 10 years of experience in the field. With a Ph.D. in Molecular and Cellular Biology, Kevin has held various roles in companies such as Adimab, University of Washington, OHSU, and Howard Hughes Medical Institute. Kevin has expertise in antibody discovery campaign management, next-generation sequencing, antibody library construction, technical training, and SOP development. Kevin is known for their exceptional contributions to the field of antibody engineering.
This person is not in any teams
This person is not in any offices
Adimab
1 followers
Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.